KR20060003860A - 내피 세포 특이적 항체 및 그의 용도 - Google Patents

내피 세포 특이적 항체 및 그의 용도 Download PDF

Info

Publication number
KR20060003860A
KR20060003860A KR1020057016552A KR20057016552A KR20060003860A KR 20060003860 A KR20060003860 A KR 20060003860A KR 1020057016552 A KR1020057016552 A KR 1020057016552A KR 20057016552 A KR20057016552 A KR 20057016552A KR 20060003860 A KR20060003860 A KR 20060003860A
Authority
KR
South Korea
Prior art keywords
antibody
tem
igg
tumor
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057016552A
Other languages
English (en)
Korean (ko)
Inventor
비벌리 테이쳐
브루스 로버츠
시로 가타오카
도모유키 다하라
나카유키 혼마
Original Assignee
기린 비루 가부시키가이샤
겐자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32966870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20060003860(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 기린 비루 가부시키가이샤, 겐자임 코포레이션 filed Critical 기린 비루 가부시키가이샤
Publication of KR20060003860A publication Critical patent/KR20060003860A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020057016552A 2003-03-04 2004-03-04 내피 세포 특이적 항체 및 그의 용도 Ceased KR20060003860A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US45185603P 2003-03-04 2003-03-04
US45185203P 2003-03-04 2003-03-04
US60/451,856 2003-03-04
US60/451,852 2003-03-04
US45246903P 2003-03-06 2003-03-06
US60/452,469 2003-03-06
US46380103P 2003-04-18 2003-04-18
US60/463,801 2003-04-18
US46530403P 2003-04-24 2003-04-24
US60/465,304 2003-04-24
US47117703P 2003-05-16 2003-05-16
US60/471,177 2003-05-16

Publications (1)

Publication Number Publication Date
KR20060003860A true KR20060003860A (ko) 2006-01-11

Family

ID=32966870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016552A Ceased KR20060003860A (ko) 2003-03-04 2004-03-04 내피 세포 특이적 항체 및 그의 용도

Country Status (11)

Country Link
US (1) US20070020271A1 (enrdf_load_stackoverflow)
EP (3) EP2267031A1 (enrdf_load_stackoverflow)
JP (2) JP4928259B2 (enrdf_load_stackoverflow)
KR (1) KR20060003860A (enrdf_load_stackoverflow)
CN (1) CN1832965B (enrdf_load_stackoverflow)
AT (1) ATE493440T1 (enrdf_load_stackoverflow)
AU (1) AU2004217442A1 (enrdf_load_stackoverflow)
BR (1) BRPI0409575A (enrdf_load_stackoverflow)
CA (1) CA2518490A1 (enrdf_load_stackoverflow)
DE (1) DE602004030764D1 (enrdf_load_stackoverflow)
WO (1) WO2004078942A2 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029045A2 (en) * 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
DE602005022757D1 (de) * 2004-12-03 2010-09-16 Morphotek Inc Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
WO2006116451A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
CA3025354A1 (en) 2006-11-09 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
EP2620451B1 (en) * 2007-04-05 2016-09-14 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
JP2013543379A (ja) * 2010-09-29 2013-12-05 モルフォテック， インコーポレイテッド 操作されたヒトエンドシアリン発現齧歯動物
US9181340B2 (en) 2011-06-14 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services TEM8 antibodies, conjugates thereof, and their use
CA3178299A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tem8 antibodies and their use
CN104931697B (zh) * 2015-05-28 2017-03-01 上海交通大学医学院附属仁济医院 Cd248+cd8+t细胞亚群在人升主动脉瘤病变过程中的作用
CN106591207B (zh) * 2016-12-07 2019-10-29 南昌大学 用于表达aif及整合有aif的重组单链抗体的菌株及该菌株的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
EP0746613B1 (en) * 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
JP2004527210A (ja) * 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
AU2002258543B2 (en) * 2001-04-11 2008-05-22 The Johns Hopkins University Endothelial cell expression patterns

Also Published As

Publication number Publication date
DE602004030764D1 (de) 2011-02-10
EP2267031A1 (en) 2010-12-29
WO2004078942A2 (en) 2004-09-16
JP4928259B2 (ja) 2012-05-09
EP1599503B1 (en) 2010-12-29
CA2518490A1 (en) 2004-09-16
ATE493440T1 (de) 2011-01-15
CN1832965B (zh) 2011-03-02
EP2264073A1 (en) 2010-12-22
CN1832965A (zh) 2006-09-13
AU2004217442A1 (en) 2004-09-16
US20070020271A1 (en) 2007-01-25
BRPI0409575A (pt) 2006-04-18
JP2006521388A (ja) 2006-09-21
WO2004078942A3 (en) 2005-04-21
EP1599503A2 (en) 2005-11-30
JP2011052002A (ja) 2011-03-17

Similar Documents

Publication Publication Date Title
JP2011052002A (ja) 内皮細胞特異的抗体およびその使用
CA2648109C (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
US8591887B2 (en) EPHA2 as a therapeutic target for cancer
JP5185815B2 (ja) 抗ｃｄ７１モノクローナル抗体および悪性腫瘍細胞を治療するためのその使用
US7090844B2 (en) Use of antibodies against the MUC18 antigen
EP0667165A1 (en) Therapeutic compositions containing monoclonal antibodies specific to human epidermal growth factor receptor
AU6784400A (en) Treatment of metastatic disease
RU2365382C2 (ru) Композиции и способы для регуляции развития сосудов
JP2016520527A (ja) 細胞表面ｇｒｐ７８に結合する抗体を使用したがんの処置
JP2025104351A (ja) 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用
CN113597304A (zh) 原发性中枢神经系统淋巴瘤的组合治疗
WO2006017759A2 (en) Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
ES2739925T3 (es) Agente específico de RANKL para el tratamiento de una enfermedad metastásica
BRPI0415541B1 (pt) uso de uma molécula inibidora de angiogênese, composição terapêutica para tratametno de câncer, e uso do anticorpo h33, produzido pelo hibridoma 13h33
WO2006029045A2 (en) Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
US20250282888A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US20060058257A1 (en) Influencing angiogenesis using CD66a
AU2006202023B2 (en) Treatment of metastatic disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000